REIv--the variable domain of an immunoglobulin x light chain--was produced by heterologous gene expression in a Gram-positive bacterium, purified to homogeneity and characterized. A host/vector combination based on secretion of Staphylococcus hyicus lipase by Staphylococcus carnosus was exploited. A gene encoding a fusion protein, composed of an aminoterminal portion of the pre-pro-peptide of S. hyicus lipase, a hexahistidine affinity tag, followed by the recognition sequence of IgA protease and REIv was constructed. Expression of the fusion gene in S. carnosus causes selective secretion and accumulation of a soluble fusion protein in the culture medium (5-10 mg/l), which can be purified from the supernatant by immobilized metal ion affinity chromatography (IMAC). REIv is released from the fusion protein with an additional threonine and proline residue at the aminoterminus (REIvTP) by site-specific cleavage with IgA protease and can be separated from the hexahistidine-tagged fusion partner and the protease by a second passage through an IMAC gel matrix. Like authentic REIv, the isolated protein (> 1 mg/l culture medium) migrates as a dimer in gel filtration chromatography and undergoes cooperative, reversible unfolding in urea. The isolated immunoglobulin REIvTP and authentic REIv have indistinguishable free energies of unfolding (approx. 26 kJ/mol, 6.3 kcal/mol).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1515/bchm3.1994.375.4.271 | DOI Listing |
Medicine (Baltimore)
November 2024
Clinical laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
This study analyzes the laboratory characteristics and prognosis of patients between PML-RARα negative APL and PML-RARα positive APL and compares the differences in order to improve the understanding of this rare APL and guide clinical diagnosis and treatment. A total of 81 patients with newly diagnosed APL based on bone marrow cell morphology were included, with 14 in the PML-RARα gene negative group and 67 in the PML-RARα gene positive group. The sex, age, peripheral blood routine test, coagulation related indicators, bone marrow cell morphology, flow cytometric immunophenotype, abnormal chromosome expression and prognosis of the 2 groups were analyzed and compared.
View Article and Find Full Text PDFEur J Cancer
January 2025
Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK. Electronic address:
Background: Ossifying fibromyxoid tumour is a rare mesenchymal soft tissue sarcoma with uncertain differentiation and variable metastatic potential.
Patients And Methods: This study offers a retrospective analysis of 23 patients diagnosed with OFMT between 1993 and 2024.
Results: The tumours most commonly arose in the extremities and trunk, with all patients undergoing surgical resection of the primary tumour.
The HIPRA-HH-2 was a multicentre, randomized, active-controlled, double-blind, non-inferiority phase IIb clinical trial comparing the immunogenicity and safety of the PHH-1V adjuvanted recombinant vaccine as a heterologous booster against homologous booster with BNT162b2. Interim results demonstrated strong humoral and cellular immune response against the SARS-CoV-2 Wuhan-Hu-1 strain and the Beta, Delta, and Omicron BA.1 variants up to day 98 post-dosing.
View Article and Find Full Text PDFFluids Barriers CNS
January 2025
Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, ON, Canada.
Background: Iduronate-2-sulfatase (IDS) deficiency (MPS II; Hunter syndrome) is a disorder that exhibits peripheral and CNS pathology. The blood brain barrier (BBB) prevents systemic enzyme replacement therapy (ERT) from alleviating CNS pathology. We aimed to enable brain delivery of systemic ERT by using molecular BBB-Trojans targeting endothelial transcytosis receptors.
View Article and Find Full Text PDFBiol Res
January 2025
School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Background: Protein palmitoylation, a critical posttranslational modification, plays an indispensable role in various cellular processes, including the regulation of protein stability, mediation of membrane fusion, facilitation of intracellular protein trafficking, and participation in cellular signaling pathways. It is also implicated in the pathogenesis of diseases, such as cancer, neurological disorders, inflammation, metabolic disorders, infections, and neurodegenerative diseases. However, its regulatory effects on sperm physiology, particularly motility, remain unclear.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!